Valuation: Roche Holding AG

Market Cap 30TCr 37TCr 32TCr 27TCr 51TCr 35,53600Cr 52TCr 3,52000Cr 1,37200Cr 17,80900Cr 1,39400Cr 1,36400Cr 58,96100Cr P/E 2026 *
20.7x
P/E 2027 * 18.4x
Enterprise Value 31TCr 38TCr 33TCr 28TCr 53TCr 36,83800Cr 54TCr 3,64900Cr 1,42200Cr 18,46200Cr 1,44600Cr 1,41400Cr 61,12000Cr EV / Sales 2026 *
4.91x
EV / Sales 2027 * 4.59x
Free-Float
88.78%
Yield 2026 *
2.69%
Yield 2027 * 2.75%
Current month+0.48%
6 months-12.57%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 249.6
Extreme 249.6
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 37TCr
-2.81%+2.93%+76.40%+127.73% 1,10900Cr
-2.21%+2.02%+49.50%+55.01% 64TCr
-1.56%+4.39%+25.19%+74.39% 46TCr
+1.20%+2.62%+41.69%+45.78% 37TCr
-0.61%+2.10%+23.43%+41.34% 30TCr
+0.32%+3.25%+0.94%+13.42% 26TCr
-1.95%+3.80%+46.31%+65.66% 23TCr
-1.10%-0.70%-14.31%-52.66% 20TCr
-2.82%+3.84%+20.81%+89.04% 18TCr
Average -1.15%+3.00%+30.00%+51.08% 41.79TCr
Weighted average by Cap. -1.48%+3.26%+43.26%+70.42%

Financials

2026 *2027 *
Net sales 6.26TCr 7.84TCr 6.71TCr 5.75TCr 11TCr 7,50300Cr 11TCr 74TCr 29TCr 3,76000Cr 29TCr 29TCr 12,44900Cr 6.55TCr 8.2TCr 7.02TCr 6.01TCr 11TCr 7,84200Cr 12TCr 78TCr 30TCr 3,93000Cr 31TCr 30TCr 13,01100Cr
Net income 1.45TCr 1.82TCr 1.55TCr 1.33TCr 2.5TCr 1,73800Cr 2.55TCr 17TCr 6.71TCr 87TCr 6.82TCr 6.67TCr 2,88300Cr 1.63TCr 2.04TCr 1.75TCr 1.5TCr 2.82TCr 1,95600Cr 2.87TCr 19TCr 7.55TCr 98TCr 7.68TCr 7.51TCr 3,24600Cr
Net Debt 1.09TCr 1.36TCr 1.16TCr 997.11Cr 1.87TCr 1,30200Cr 1.91TCr 13TCr 5.03TCr 65TCr 5.11TCr 5TCr 2,16000Cr 401.96Cr 503.17Cr 430.81Cr 368.83Cr 693.06Cr 48TCr 706.7Cr 4.77TCr 1.86TCr 24TCr 1.89TCr 1.85TCr 80TCr
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
1,03,249
Date Price Change Volume
20/26/20 CHF 323.90 0.00% 582
19/26/19 CHF 323.90 0.00% 57,386
18/26/18 CHF 323.90 0.00% 3,22,267
17/26/17 CHF 323.90 0.00% 1,00,964
14/26/14 CHF 323.90 0.00% 70
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
371.80CHF
Average target price
370.31CHF
Spread / Average Target
-0.40%

Quarterly revenue - Rate of surprise